RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
May 21, 2019 07:00 ET
|
RedHill Biopharma Ltd.
Rob Jackson joins as Vice President of MarketingRobert J. Gilkin, Jr. joins as Vice President of Market AccessSteven Thomasian to join as Vice President of Supply Chain TEL-AVIV, Israel and RALEIGH,...
RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
October 24, 2018 08:00 ET
|
RedHill Biopharma Ltd.
RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint, with top-line results...
Positive Bioavailability Studies of RedHill's BEKINDA(TM) to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting
March 02, 2015 07:00 ET
|
RedHill Biopharma Ltd.
The results from two positive bioavailability studies, previously reported by the Company, demonstrate the safety and tolerability of BEKINDA™ and support the European marketing application...
RedHill Biopharma Announces Full Exercise of Underwriters' Over-Allotment Option
February 18, 2015 09:56 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 18, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
Pressure BioSciences, Inc. to Discuss Third Quarter 2011 Financial Results and Provide Business Update
November 08, 2011 16:42 ET
|
Pressure BioSciences, Inc.
SOUTH EASTON, Mass., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its...